Click on the date you’d like to join us to register for this event!
Wednesday, March 31, at 6 PM CST
Thursday, April 1, at 12:30 PM CST
Dear DAPA members,
The AbbVie Women’s Health Organization is pleased to connect with the community of Pharmacists in the Dallas area.
We recognize your pharmacies provide services that cover a wide variety of medications, for diverse disease states, patient monitoring, and frequent communications with a diversity of healthcare providers. We as MSLs work to advance R&D in Women’s Health, promoting scientific communications that are fair and balanced and non-promotional in nature. We are here to support all healthcare providers, including pharmacists, deliver the best care to their patients!
Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids have been primarily managed by surgery and are the leading reason for the hysterectomies performed in the U.S. ORIAHNN (Elagolix+Estradiol/NETA) is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
With the ultimate goal to bring awareness, and elevate Women’s healthcare and the scientific acumen of our healthcare givers in our community, I will be offering a virtual educational program to connect with all of you, and provide a brief overview of uterine fibroids disease state and the phase III clinical trial data supporting our newest product indicated for heavy menstrual bleeding associated with uterine fibroids (FDA approved in 2020, https://www.rxabbvie.com/pdf/oriahnn_pi.pdf)
I will be offering two options for you to join via zoom,
Wed Mar 31, at 6 pm CT
Thurs April 1, at 12:30 pm CT
I look forward to having you join!
As your local MSL, please count on me as your local scientific peer and resource.
Thank you for your devoted service to all our patients,
Respectfully,
Maria J. Torres, PhD
Medical Science Liaison – Women’s Health | TX MS LA
Women’s Health MSL Organization
US Medical Affairs
BIO: Maria Jose Torres, PhD
Dr. Torres brings 10 years of academic research experience in the Women’s Health arena with a focus on estrogens and estrogen-dependent disease. She completed her bachelor’s degree in Biochemistry in her home country, Uruguay, and then moved to the United States to pursue her Doctorate in Bioenergetics at East Carolina University. Her research work, discovering novel non-genomic mechanisms of metabolic control by estrogens impacted by menopause was published in the top journal Cell, and she was soon recruited to Duke University. Working at the Duke Molecular Physiology Institute, she was a Duke Scholar in Molecular Medicine, she received a Postdoctoral Fellowship through the American Heart Association, and was the developer and leader of a clinical-translational research program to investigate the long-term cardiometabolic toxicity of chemotherapy in breast cancer survivors.
Mission-driven to advance Women’s Health research and healthcare, Dr. Torres recently joined the AbbVie Women’s Health Organization as a Medical Science Liaison, supporting the territory o
